ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Biotechnology

Fujifilm to make Novavax coronavirus vaccine component in UK

Production will fulfill order from British government for 60m doses

U.S. President Donald Trump tours Fujifilm Diosynth Biotechnologies' Bioprocess Innovation Center in the state of North Carolina on July 27.   © Reuters

TOKYO -- Japan's Fujifilm Holdings said Monday that it has won an order to produce a key component of American biotechnology company Novavax's coronavirus vaccine candidate at a site in the U.K.

Fujifilm subsidiary Fujifilm Diosynth Biotechnologies will churn out the antigen component starting in early 2021. The output will fulfill an order by the British government for 60 million doses.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more